Brilliant Violet 421™ anti-mouse NK-1.1 Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Mouse

Immunogen

NK-1⁺ cells from mouse spleen and bone marrow

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Preparation

The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.

Concentration

µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

SB - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤ 0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using µl sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Excitation Laser

Violet Laser (405 nm)

Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation^1,2, complement-dependent cytotoxicity³, in vivo depletion^4,5,9,10, mediation of in vitro redirected lysis⁶, blocking of NK cell function⁷, induction of proliferation⁸, immunohistochemical staining of frozen sections¹¹, immunofluorescence microscopy¹¹, and spatial biology (IBEX)^16,17. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 108712).

Additional Product Notes

Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

Application References

(PubMed link indicates BioLegend citation)

1. Carlyle JR, et al. 1999. J. Immunol. 162:5917. (IP)
2. Sentman CL, et al. 1989. Hybridoma 8:605. (IP)
3. Koo GC, et al. 1984. Hybridoma 3:301. (Cyt)
4. Sentman CL, et al. 1989. J. Immunol. 142:1847. (Deplete)
5. Koo GC, et al. 1986. J. Immunol. 137:3742. (Deplete)
6. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
7. Kung SK, et al. 1999. J. Immunol. 162:5876. (Block)
8. Reichlin A, et al. 1998. Immunol. Cell Biol. 76:143.
9. Drobyski W, et al. 1996. Blood 87:5355. (Deplete)
10. Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (Deplete)
11. Kanwar JR, et al. 2001. J. Natl. Cancer Inst. 93:1541. (IHC, IF)
12. Kroemer A, et al. 2008. J. Immunol. 180:7818. PubMed
13. Kim JY, et al. 2009. Exp Mol Med. 30:288. PubMed
14. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
15. Lee H, et al. 2014. Invest Ophthalmol Vis Sci. 55:2885. PubMed
16. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
17. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed

Product Citations

1. Garber C, et al. 2019. Nat Neurosci. 1.802777778. PubMed
2. Zhao Z, et al. 2021. Nat Commun. 12:4355. PubMed
3. Schnell A, et al. 2021. Cell. 184:6281. PubMed
4. Bettke JA, et al. 2022. Infect Immun. 90:e0007022. PubMed
5. Edwards SC, et al. 2023. J Exp Med. 220: . PubMed
6. Nettersheim FS, et al. 2023. Front Cardiovasc Med. 9:1076808. PubMed
7. Tao X, et al. 2022. J Exp Med. 219:. PubMed
8. Harapas CR, et al. 2022. Sci Immunol. 7:eabi4611. PubMed
9. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
10. Seclì L, et al. 2023. J Immunother Cancer. 11:. PubMed
11. Wiesner DL, et al. 2020. Cell Host Microbe. 614:27. PubMed
12. Machata S, et al. 2021. Front Immunol. 11:565869. PubMed
13. Minutti CM, et al. 2019. Immunity. 50:645. PubMed
14. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
15. Li Q et al. 2018. Immunity. 48(2):258-270 . PubMed
16. Godbersen-Palmer C, et al. 2020. J Immunol. 204:2973. PubMed
17. Bhattacherjee A, et al. 2019. Commun Biol. 2:450. PubMed
18. Adams RCM, et al. 2019. Mediators Inflamm. 2019:9160941. PubMed
19. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
20. Lin J, et al. 2017. Sci Rep. 7:41722. PubMed
21. Garcia LR, et al. 2021. Nat Commun. 12:3364. PubMed
22. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
23. Yang P, et al. 2022. Nat Commun. 13:5782. PubMed
24. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
25. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
26. Gordon E, et al. 2015. Proc Natl Acad Sci U S A. 112: 13075 - 13080. PubMed
27. Duan H, et al. 2021. J Clin Invest. 131:. PubMed
28. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
29. Santecchia I, et al. 2019. PLoS Pathog. 15:e1007811. PubMed
30. Hu M, et al. 2020. Cancer Immunol Res. 8:1150. PubMed
31. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
32. Baomei Wang et al. 2019. Cell reports. 26(6):1614-1626 . PubMed
33. Kim DK, et al. 2022. Nat Commun. 13:6292. PubMed
34. Saber M, et al. 2021. J Neurosci Res. 99:1136. PubMed
35. Collins PL et al. 2018. Cell. 176(1-2):348-360 . PubMed
36. Alexander Mildner et al. 2017. Immunity. 46(5):849-862 . PubMed
37. Rasid O, et al. 2020. Cell Reports. 29(12):3933-3945.e3.. PubMed
38. Damgaard RB et al. 2016. Cell. 166(5):1215-1230 . PubMed
39. Hakim R, et al. 2021. J Neurosci. 41:8441. PubMed
40. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
41. Dhayade S, et al. 2020. Nutrients. 12:. PubMed
42. Liu H et al. 2017. Cell host & microbe. 22(5):653-666 . PubMed
43. Jolly A, et al. 2022. Cell Rep Methods. 2:100315. PubMed
44. Boulch M, et al. 2021. Sci Immunol. 6:. PubMed
45. Tomita T, et al. 2021. Nat Commun. 12:3655. PubMed
46. Dyer DP et al. 2019. Immunity. 50(2):378-389 . PubMed
47. Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed
48. Patil ND, et al. 2022. Front Immunol. 13:818015. PubMed
49. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed

RRID

AB_10895916 (BioLegend Cat. No. 108731)
AB_10895916 (BioLegend Cat. No. 108741)
AB_10895916 (BioLegend Cat. No. 108732)

Antigen Details

Structure

NKR-P1 gene family

Distribution

NK and NK-T cells in the NK1.1 mouse strains (C57BL, FVB/N, NZB)

Function

NK cell activation, IFN-γ production, cytotoxic granule release

Cell Type

NK cells, NKT cells

Biology Area

Immunology, Innate Immunity

Antigen References

1. Lanier LL. 1997. Immunity 6:371.
2. Yokoyama WM, et al. 1993. Ann. Rev. Immunol. 11:613.
3. Koo GC, et al. 1986. J. Immunol. 137:3742.
4. Giorda R, et al. 1991. J. Immunol. 147:1701.

Gene ID

17059 View all products for this Gene ID

Specificity (DOES NOT SHOW ON TDS):

NK-1.1

Specificity Alt (DOES NOT SHOW ON TDS):

NK-1.1

App Abbreviation (DOES NOT SHOW ON TDS):

FC,SB

UniProt

View information about NK-1.1 on UniProt.org

Documentation

• Technical data sheet
• Certificate of Analysis
• Material Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?

It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.

Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?

Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.

Are other fluorophores compatible with IBEX?

Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.

The same antibody works in one tissue type but not another. What is happening?

Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.

How can I be sure the staining I’m seeing in my tissue is real?

In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.

Other Formats

Certificate of Analysis